Physicians choose valued sales forces
Physicians in nine specialty groups collectively agreed for the third consecutive year that Pfizer Labs' sales force is the most valuable, according to health care consulting firm Scott-Levin's study "Sales Force Structures & Strategies 1997-1998."
Physicians in nine specialty groups collectively agreed for the third consecutive year that Pfizer Labs' sales force is the most valuable, according to health care consulting firm Scott-Levin's study "Sales Force Structures & Strategies 1997-1998."
Strong product lines helped Pfizer reps cinch their grip on the number one spot, according to Scott-Levin. Pfizer launched Aricept, an Alzheimer's disease therapy, and received a new indication for its antidepressant Zoloft.
Pfizer Labs' sales force had the added bonus of co-promoting Lipitor, a powerful cholesterol-reducer manufactured by Parke-Davis.
Merck's sales force was ranked number one by internal medicine specialists, cardiologists, rheumatologists and infectious disease specialists.
Wyeth-Ayerst's sales force was preferred by obstetricians and gynecologists, orthopedic surgeons and physical medicine and rehabilitation specialists.
SmithKline Beecham's sales force ranked first with general surgeons and neurosurgeons. Schering Plough was first with allergists and otorhinolaryngologists. Astra Merck was a favorite with gastroenterologists and Lilly was tops with psychiatrists. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
